In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

episodes classified as atrial tachycardia. The AF Suppression Algorithm reduced symptomatic AF burden from 2.50% in the control group to 1.87% in the treatment group, a relative difference of 25%.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Such techniques can be automatically applied using implantable cardioverter defibrillators (ICDs) and offer the potential for painless termination of ventricular tachycardia (VT). Reduction in ...

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy TA117 24 January 2007 24 January 2007 Methadone and buprenorphine ...

Our vision is to innovate and incorporate promising technologies to communicate freely available, high-priority, high-quality content, which accelerates scientific progress and advances heart and ...